iBio (IBIO) Change in Accured Expenses (2010 - 2026)

iBio (IBIO) has 17 years of Change in Accured Expenses data on file, last reported at $415000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 72.92% year-over-year to $415000.0 in Q1 2026; TTM through Mar 2026 was $242000.0, a 112.51% increase from a year earlier, with the FY2025 full-year figure at -$758000.0, up 56.08% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $415000.0, down from $567000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for IBIO reached as high as $2.4 million in Q4 2022 and fell as low as -$1.3 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$66000.0 across 5 years, with a median of $8000.0 in 2024.
• Across the five-year window, Change in Accured Expenses plunged 1407.29% in 2023 and soared 6987.5% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $2.4 million in 2022, then plunged by 100.29% to -$7000.0 in 2023, then surged by 214.29% to $8000.0 in 2024, then surged by 6987.5% to $567000.0 in 2025, then slipped by 26.81% to $415000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $415000.0 in Q1 2026, $567000.0 in Q4 2025, and -$686000.0 in Q3 2025.